Effect of antisickling agents and lactadherin treatment on RBC extrusion from ex vivo whole blood clots. Number of RBCs extruded from clots, in the absence (−) or presence (+) of FXIIIa inhibitor T101 (20 µM), obtained from sickle cell patients receiving (n = 12) or not (n = 11) HU treatment (A) with SS mice treated in vivo with 5HMF (100 mg/kg of body weight; oral gavage; n = 13) or saline (n = 6) (B) or whole blood from SS mice treated ex vivo with phosphatidylserine inhibitor, lactadherin (1 µM; n = 3-10) (C). *P < .05, **P < .01, ***P < .001. IIa, thrombin.